Jarvik Heart Inc (Jarvik) is a developer and manufacturer of miniaturized heart assist devices. The company’s products include ventricular assist devices and miniature heart assist device valveless Jarvik 2000 for infants and children. Its ventricular assist devices are used to support and rehabilitate patients with severe heart failure. Jarvik’s products are used for the treatment of severe heart failure. The company markets its products in France, Germany, Greece, Italy, Monaco, Switzerland, Japan, and the US. It operates through its manufacturing facility located in Midtown Manhattan. Jarvik is headquartered in New York, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Jarvik Heart Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
Jarvik Heart Inc Company Overview
Jarvik Heart Inc Company Snapshot
Jarvik Heart Inc Pipeline Products and Ongoing Clinical Trials Overview
Jarvik Heart Inc – Pipeline Analysis Overview
Jarvik Heart Inc - Key Facts
Jarvik Heart Inc - Major Products and Services
Jarvik Heart Inc Pipeline Products by Development Stage
Jarvik Heart Inc Ongoing Clinical Trials by Trial Status
Jarvik Heart Inc Pipeline Products Overview
Jarvik 2000 Heart - Bridge To Transplant
Jarvik 2000 Heart - Bridge To Transplant Product Overview
Feb 11, 2022: Yashoda Hospitals, Hyderabad, India gives a new lease of life to 31 Year-old Footballer from Uganda through L-VAD (Left Ventricular Assist Device)
Apr 23, 2018: Bambino Gesù: Miniaturized Heart Pump Saves the Life of Three-Year-Old Girl
Oct 21, 2016: Jarvik Heart Receives FDA Approval for Clinical Trial of Miniature Heart Assist Device for Infants and Children
Dec 05, 2013: Jarvik Heart Obtains Regulatory Clearance For Jarvik 2000 Heart In Japan
Aug 14, 2012: Jarvik Heart Announces Full FDA Approval Of Jarvik 2000 Destination Therapy Trial
Apr 20, 2012: NERI Announces Additional $18m NIH Contract To Support PumpKIN Program
Feb 27, 2012: Jarvik Heart Announces FDA Conditional Approval Of Trial Using Jarvik 2000 Heart For DT
Jul 12, 2005: FDA Approves Pivotal Trial Of The Jarvik 2000 FlowMaker
May 10, 2005: Jarvik Heart Announces CE Mark Approval For Jarvik 2000 FlowMaker
Apr 27, 2004: Jarvik Heart Awarded Major NIH Contract To Develop Heart Pump For Children